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PKCe switches Aurora B speciﬁcity to exit the
abscission checkpoint
Tanya Pike1, Nicola Brownlow1,w, Svend Kjaer2, Jeremy Carlton3 & Peter J. Parker1,3
The ‘NoCut’, or Aurora B abscission checkpoint can be activated if DNA is retained in the
cleavage furrow after completion of anaphase. Checkpoint failure leads to incomplete
abscission and a binucleate outcome. These phenotypes are also observed after loss of
PKCe in transformed cell models. Here we show that PKCe directly modulates the
Aurora B-dependent abscission checkpoint by phosphorylating Aurora B at S227. This
phosphorylation invokes a switch in Aurora B speciﬁcity, with increased phosphorylation of a
subset of target substrates, including the CPC subunit Borealin. This switch is essential for
abscission checkpoint exit. Preventing the phosphorylation of Borealin leads to abscission
failure, as does expression of a non-phosphorylatable Aurora B S227A mutant. Further,
depletion of the ESCRT-III component and Aurora B substrate CHMP4C enables abscission,
bypassing the PKCe–Aurora B exit pathway. Thus, we demonstrate that PKCe signals through
Aurora B to exit the abscission checkpoint and complete cell division.
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T
he existence of a ﬁnal ‘NoCut’ checkpoint before exit from
cytokinesis has been deﬁned by a number of groups in
yeast, worms and mammalian systems1–7. This checkpoint,
operating at the point of no return for precise and successful
self-renewal, is dependent on Aurora B kinase activity and is
engaged by the presence of chromatin trapped in the cytokinesis
furrow. The localization of Aurora B to key mitotic structures
throughout mitosis, including the midbody during cytokinesis
indicates a fundamental role for the kinase in successful
completion of mitosis8. Aurora B and components of the
chromosomal passenger complex (CPC) are known to interact
with and trigger phosphorylation of downstream substrates to
effect completion of cytokinesis; these substrates include the
following: MgcRacGap9; vimentin10; PRC1 (ref. 11); MKLP1
(ref. 12); and CHMP4C (refs 5,13).
The ﬁnal stage of cytokinesis, abscission, follows ordered
recruitment of the endosomal sorting complexes required for
transport (ESCRT) machinery to the midbody leading to
constriction of ESCRT-III ﬁlaments bringing the membranes
together until scission can occur (reviewed in ref. 14). The
ESCRT-III subunit CHMP4C is a key player in the Aurora B
abscission checkpoint, stalling abscission due to the presence of
retained chromatin in the furrow through interaction with the
CPC subunit Borealin and phosphorylation by Aurora B5,15.
Phosphorylation of CHMP4C at S210 maintains the subunit in a
closed, inactive conformer, unable to polymerize with other
ESCRT-III subunits13. The AAA-ATPase VPS4 has also been
shown to be controlled in an Aurora B-dependent manner
through CHMP4C association; VPS4 localization to the midbody
ring is inhibited when the abscission checkpoint is engaged,
thereby preventing abscission4. The tight regulation of this
ﬁnal process in cell division is the ultimate protective measure
against a chromosome non-disjunction error that could lead to
unequal inheritance between the two daughter cells and genome
instability.
Protein kinase C (PKC) has been implicated in completion of
the ﬁnal stages of mitosis16–19. In particular, activity of the
epsilon isoform (PKCe) has been shown to be required for
successful exit from cytokinesis through a combination of
signalling pathways involving RhoA (refs 17,18) and ZO-1
(ref. 19). Knockdown or inhibition of PKCe results in failure to
complete abscission, the ﬁnal step in severing the bridge between
the two daughter cells; abscission failure typically leads to
polyploidization. PKCe, unlike Aurora B, has a unique role in
these control processes not being required in ‘normal’ diploid
cells but seemingly playing a critical role in a subset of
transformed cells18,20. This prompted us to investigate whether
this PKCe conditional action was linked to the engagement of
Aurora B in the abscission pathway.
Here we report PKCe regulation of Aurora B is required for
exit from the abscission checkpoint. We demonstrate that PKCe
directly phosphorylates Aurora B at S227 when localized to the
midbody. S227 phosphorylation induces a switch in Aurora B
substrate speciﬁcity promoting the phosphorylation of the CPC
subunit Borealin at S165 to facilitate abscission exit. This
signalling cascade results in the localization of the ESCRT-III
component CHMP4C to the midbody ring enabling the ﬁnal
scission event.
Results
PKCe regulates Aurora B at the midbody during cytokinesis.
On inhibition, PKCe accumulates at and stabilizes the midbody17,
hence to assess what process(es) it might engage there, we
screened a midbody protein-biased peptide array for candidate
substrates of PKCe (Fig. 1a). This identiﬁed a number of
candidates for which phosphorylation was greater than the
optimized pseudosubstrate site peptide control (Supplementary
Fig. 1a and Supplementary Data 1). Included in these ‘hits’ was
the protein kinase Aurora B, where S227, a site proximal to the
activation loop T232 phosphorylation site, was identiﬁed. An
in vitro kinase assay with the two proteins demonstrated a
twofold increase in 32P-phosphate incorporation into Aurora B
catalysed by PKCe (Supplementary Fig. 1b). We raised an
antibody selective for phosphorylated S227 in Aurora B, and this
revealed PKCe phosphorylation of this Aurora B site in vitro
(Fig. 1b). Phosphorylation of the S227 site has been identiﬁed
in vivo in mass spectrometry screens (Supplementary Data 1),
and notably the site is conserved within the Aurora family of
kinases and indeed within higher eukaryotes (Fig. 1c).
On the basis of localization of the endogenous proteins by
immunoﬂuorescence (Supplementary Figs 1c and 2b) and more
directly on proximity ligation assays, Aurora B and PKCe were
found to co-localize at the midbody in DLD1 cells as observed for
Aurora B and INCENP subunits of the CPC (Fig. 1d and
Supplementary Fig. 1d). Furthermore, assessment of S227
phosphorylation in DLD1 cells demonstrated that a subset of
Aurora B phosphorylated at this site localizes at the midbody
(note the nuclear recognition is nonspeciﬁc and not eliminated by
knockdown of Aurora B using siRNA (Supplementary Fig. 1e)
nor expression of a non-phosphorylatable S227A mutant
(Supplementary Fig. 1f; see further below)). The midbody
phospho-S227 immunoreactivity is sensitive to inhibition of
PKCe after a 30min treatment with the selective inhibitor
BLU577 (compound 18, ref. 21; Fig. 1e and Supplementary
Fig. 1f). Analysis of S227 phosphorylation through mitosis
revealed chromatin-associated staining of Aurora B S227
phosphorylation in mitosis (which was absent following Aurora
B knockdown (Supplementary Fig. 1f, lower panel)) but not
during telophase (Supplementary Fig. 1g). Phosphorylation of the
activating T232 residue was not inﬂuenced by PKCe inhibition
(Supplementary Fig. 1h), nor by expression of the S227A mutant
of Aurora B (Supplementary Fig. 1i).
Aurora B localization at the midbody. On close inspection
of the midbody, we observed that Aurora B phosphorylated on
T232 localizes to the midbody arms, the midbody ring and
overlays with total Aurora B staining albeit concentrated in the
midbody ring (Supplementary Fig. 2a). By contrast Aurora B
phosphorylated on S227 exclusively localizes to the midbody ring,
We note here that Hu et al.22 describe Aurora B (both
endogenous and green ﬂuorescent protein (GFP)-tagged) as
being excluded from the stem body and localizing to the ﬂanking
regions, however we clearly observe this ring structure
localization in both endogenous, antibody-stained samples
(Supplementary Fig. 2a) and GFP-Aurora B-expressing cells
(Supplementary Fig. 2b). Certainly, most of the Aurora B appears
located on the midbody arms and it may be the case that it is
difﬁcult to visualize Aurora B that is localized in the midbody ring
without speciﬁc antibodies for that compartment.
Successful abscission requires Aurora B S227 phosphorylation.
To assess the role of this phosphorylation in Aurora B action, we
established cell lines that express an inducible Aurora B wild type
(WT) or the S227A mutant at similar levels (Supplementary
Fig. 2c). Interestingly, expression of the S227A mutant increased
the number of binucleated cells (Fig. 2a) as a result of abscission
failure (Fig. 2b and Supplementary Fig. 2d), phenocopying PKCe
inhibition. Cells expressing Aurora B S227A did not fail
abscission due to a prolonged delay or arrest during cytokinesis
(Supplementary Fig. 2e–g). Comparing Aurora B WT and S227A
expressing cells, no signiﬁcant increase in the number of cells in
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cytokinesis (Supplementary Fig. 2e) nor difference in the time
from telophase onset to midbody dissolution (for either successful
or failed cytokinesis) was observed (Supplementary Fig. 2f,g).
However, the behaviour of S227A-expressing cells was associated
with an increase in DNA in the furrow as evidenced by a
substantial increase in Lap2b-positive structures in the furrow
(Fig. 2c,d); again this phenocopied PKCe inhibition with BLU577.
The abscission failure was not a function of mislocalization of
Aurora B itself (Supplementary Fig. 2h) nor of any component of
the CPC (Supplementary Fig. 3), as inhibition of PKCe with
BLU577 or expression of the S227A mutant followed the same
cell cycle pattern of subcellular distribution as the WT.
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Figure 1 | PKCe speciﬁcally phosphorylates Aurora B S227 at the midbody during cytokinesis. (a) A midbody protein-biased peptide array of PKCe
putative substrates was assayed for 32P-ATP incorporation and normalized to the pseudosubstrate peptide as a positive control. Data for all peptides
analysed in Supplementary Data 1. (b) In vitro kinase assay of PKCe and Aurora B with and without the PKC inhibitor bis-indolylmeleimide I (BIM) (1 mm).
(c) Protein sequence alignment of human Aurora kinase family members and Aurora B of various species. S227 (human Aurora B sequence) is highlighted
in red, T232 is boxed in red. (d) Proximity ligation assay between Aurora B and PKCe in DLD1 GFP-Aurora B WT cell line. The interaction between CPC
members Aurora B and INCENP served as a positive control for this assay. Primary antibodies against the endogenous proteins were used for the detection
of Aurora B, PKCe and INCENP. DAPI (blue), proximity ligation assay (PLA) (red), GFP-Aurora B (green). Scale bar, 10mm. (e) Confocal imaging shows
Aurora B pS227 (green) staining at the cytokinesis midbody (tubulin—red) in DLD1 cells (white arrows and inset) and not in the presence of the PKCe
selective inhibitor BLU577 (500nM) for 30min. Cells were scored for the presence or absence of Aurora B pS227 at the midbody (statistics analysed by
Student’s t-test; ****Po0.0001; error bars represent mean±s.e.m.). A minimum of 30 high-resolution, single-cell images per condition from 12
experiments in two different cell lines were acquired, a representative image is shown here. Scale bar, 10mm.
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Phosphorylation of S227 alters Aurora B substrate repertoire.
It would be plausible to think that PKCe-mediated
phosphorylation of Aurora B might be inhibitory to Aurora B,
and this might trigger exit from the abscission checkpoint.
However, comparing recombinant Aurora B that is S227/T232-
phosphorylated (WT) or T232-phosphorylated only (S227A)
demonstrated equivalent ATP-binding capabilities (Supplementary
Fig. 4a) and also equal phosphotransferase activities towards the
substrate histone H3 S10 (Supplementary Fig. 4b), indicating that
intrinsic catalytic activity is not affected. This led to the
hypothesis that there was not a loss of function but a change of
function associated with S227 phosphorylation, reﬂected in
altered substrate recognition. To assess this hypothesis, we
screened a peptide array of Aurora B substrate sites (Fig. 3a,
Supplementary Fig. 4c and Supplementary Data 2). This revealed
that compared with the S227A mutant, the doubly phosphory-
lated protein has a strong preference and indeed much greater
activity towards a subset of sites, with a 410-fold increase in
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Figure 2 | Aurora B S227 phosphorylation is required for successful completion of cytokinesis. (a,b) Cells where PKCe is inhibited and/or Aurora B
cannot be S227 phosphorylated do not undergo successful abscission. (a) The number of binucleate cells was assessed after 24 h induction of GFP-Aurora
B WT (4.07%±1.45), GFP-Aurora B S227A (12.03%±2.27)±BLU577 (500nM) (WT 9.97%±2.01 versus S227A 14.5%±2.94) expression in the DLD1
cell lines. Graph represents the mean (±s.e.m.) of three independent experiments of 4500 scored cells per condition. Student’s t-test, not signiﬁcant
(NS)¼ P40.05, *¼ Pr0.05, **¼ Pr0.01, ***¼ Pr0.001. (b) Wide-ﬁeld time-lapse microscopy of DLD1 GFP-Aurora B cell lines. Cells were scored for
the outcome of cytokinesis where failed cytokinesis is a binucleate cell and successful cytokinesis resulted in two daughter cells. Cells were induced for
GFP-Aurora B expression for 16 h before image acquisition. Graph represents the mean (±s.e.m.) of three independent experiments where a minimum of
100 cells were scored per condition. Two-way analysis of variance (ANOVA), ***¼ Pr0.001. (c,d) There is an increase in cells with DNA trapped in the
cytokinesis furrow if PKCe is inhibited and Aurora B cannot be phosphorylated on S227. (c) Confocal images of DLD1 GFP-Aurora B (green) cell lines
stained for Lap2b (red) to identify DNA (DAPI—blue) bridging during cytokinesis. Scale bar, 10mm. (d) DLD1 GFP-Aurora B cell lines, which stably express
RFP-Lap2b were assessed for the presence of a Lap2b-positive bridge as they underwent cytokinesis (WT 6.25%±12.5 versus S227A 43.125%±19.2; left
panel) and the outcome of cytokinesis (binucleate cells: WT 6.25%±12.5 versus S227A 80.9%±21.5; right panel). Graph represents the mean (±s.e.m.)
of three independent experiments where a minimum of 100 cells scored per condition. Two-way ANOVA, *¼ Pr0.05, ***¼ Pr0.001.
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Figure 3 | Aurora B phosphorylated on S227/T232 has unique set of substrates including Borealin S165. (a) A peptide array of known Aurora B
substrates compared the phosphorylation of peptides by either doubly phosphorylated (WT) Aurora B to those phosphorylated by singly phosphorylated
(S227A) Aurora B. Graph shows ratio of ATP incorporation into peptides phosphorylated by Aurora B WT and S227A recombinant protein. Data for all
peptides analysed in Supplementary Data 2. (b) In vitro kinase assay to detect Borealin Ser165 phosphorylation by recombinant Aurora B(WT) or (S227A)
protein. (c,d) DLD1 cells were induced to express GFP-Borealin WTor GFP-Borealin S165A for 16 h before analysis. (c) Representative confocal images of
GFP-Borealin cells in each phase of mitosis and cytokinesis. Scale bar, 10mm. (d) DLD1 cells induced to express GFP-Borealin were scored for the outcome
of cytokinesis, successful cytokinesis resulting in two daughter cells or failed cytokinesis resulting in a binucleate cell. Graph is the mean (±s.e.m.) of three
independent experiments where more than 100 cells per condition were scored. Two-way analysis of variance, **¼ Pr0.01.
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phosphorylation of the three top hits: H3F3A; Desmin; and
Borealin. Phosphorylation of Borealin S165 has been identiﬁed
previously in a mitotic phosphoproteome screen23 and was also
recognized as a direct substrate of Aurora B24,25. As part of the
chromosome passenger complex required for cytokinesis25 and
known to bind to abscission complex component CHMP4C (refs
5,13) this last target provided a candidate for relaying the effect of
PKCe phosphorylation of Aurora B on S227.
A phospho-speciﬁc antibody was raised against Borealin S165,
and by in vitro kinase assay with recombinant Aurora B we were
able to detect phosphorylation at this site in the presence of WT
(pS227/pT232) Aurora B but not Aurora B 227A (pT232 only)
(Fig. 3b), conﬁrming this site in vitro as a substrate for the
S227/T232-phosphorylated Aurora B.
To determine whether Borealin phosphorylation was part of
the regulatory cascade involved in this pathway, we stably
expressed an inducible WT or S165A mutant GFP-Borealin in
DLD1 cells (Fig. 3c). We observed that like the Aurora B S227A
mutant, expression of the Borealin S165A mutant caused
abscission failure in 42.7% (±14.7) cells undergoing cytokinesis
(Fig. 3d). The implication is that with retained DNA in the furrow
causing engagement of the Aurora B-dependent abscission
checkpoint, PKCe acts to phosphorylate Aurora B, which in
turn phosphorylates Borealin to trigger completion of
abscission—failure of any of these steps causing abscission failure.
The ESCRT-III component CHMP4C has been shown to
regulate the timing of exit from cytokinesis and abscission in
response to activation of the Aurora B-dependent abscission
checkpoint5,13. Its presence, however, is dispensable for this
process as cells may still complete abscission after knockdown of
CHMP4C (ref. 5). We hypothesized that if CHMP4C were the
effector for signalling through PKCe–Aurora B–Borealin after
engagement of the abscission checkpoint, loss of the protein
would overcome the failure of cytokinesis we observe when
signalling through this cascade is perturbed. Following
knockdown of CHMP4C with each of three targeted siRNAs in
the DLD1 GFP-Aurora B cell lines, we observed rescue of the
binucleate cell phenotype elicited by Aurora B S227A (Fig. 4a and
Supplementary Fig. 5a). Similarly, knockdown of PKCe and the
associated binucleate cell phenotype could also be rescued by
knockdown of CHMP4C (Fig. 4b), suggesting that exit from
cytokinesis after engagement of the abscission checkpoint is being
regulated by signalling through PKCe.
Localization of CHMP4C is perturbed with PKCe inhibition.
After abscission checkpoint activation, CHMP4C is retained on
the midbody arms due to the inhibitory phosphorylation at
S210 by Aurora B5,13,15. This prevents the translocation of
CHMP4C to the midbody ring, where the ﬁnal scission event
is to take place. When considering the observations that
S227/T232-phosphorylated Aurora B localizes to the midbody
ring (Supplementary Fig. 2a) and the requirement for CHMP4C
in the cytokinesis failure phenotype (Supplementary Fig. 5a) we
hypothesized that the localization of CHMP4C may be inﬂuenced
by signalling through PKCe.
Transiently expressed HA-CHMP4C in HeLa cells was
distributed as previously described5. During early cytokinesis,
CHMP4C is present on the midbody arms, adjacent to the
midbody ring (as can be demonstrated by two peaks in the green
channel on the pixel intensity proﬁles), whilst during late
cytokinesis it is concentrated within the midbody ring (single
green peak of the pixel intensity proﬁle; Supplementary Fig. 5b).
CHMP4C, which cannot be phosphorylated by Aurora B to
regulate abscission timing (HA-CHMP4C S210A)5,13, is restricted
to the midbody arms, indicating that phosphorylation of this site
is required for recruitment/retention at the midbody ring.
Interestingly, treatment of these cells with the PKCe inhibitor
BLU577 similarly restricts the localization of CHMP4C to the
midbody arms, adjacent to the midbody ring (Supplementary
Fig. 5b). On transient expression of HA-CHMP4C in DLD1
(Fig. 4c) or HEK293 GFP-Aurora B-expressing cells
(Supplementary Fig. 5d) we observed co-localization with
Aurora B in the midbody ring. The midbody localization of
CHMP4C was restricted to the midbody arms in DLD1 cells or
completely lost in HEK293 cells on co-expression of Aurora B
S227A, indicating that in these models localization to the
midbody is dependent on the S227/T232-phosphorylated
Aurora B. When HA-CHMP4C S210A was transiently
expressed in these cells, it was again localized to the midbody
arms, independent of PKCe and Aurora B activity or
phosphorylation (Supplementary Fig. 5c,d). It has been noted
elsewhere that the ESCRT machinery may be dispensable for
abscission in HEK293 cells26, however we observe clear
localization of GFP-Aurora B WT and S227A to the midbody
and context-dependent exogenous CHMP4C co-localization in
these cells also.
Interestingly, when HA-CHMP4C (WT or mutant) was
transiently expressed with GFP-Borealin in the DLD1 cell line,
we again see phenocopy of the localization of CHMP4C when
S165 cannot be modiﬁed (Fig. 4d). Speciﬁcally, it was observed
that in GFP-Borealin (WT)-expressing cells, CHMP4C can
localize to the midbody ring, while its localization is restricted
to the midbody arms if GFP-Borealin (S165A) is expressed.
Capalbo et al.13 propose that phosphorylation of CHMP4C
S210 by Aurora B maintains CHMP4C in a closed conﬁguration
before abscission, therefore the localization of the S210A mutant
would not be subject to regulation by the CPC, and could still
localize to the midbody forming the open conformation
membrane-associated polymers required. We therefore suggest
that PKCe ultimately drives the localization of CHMP4C through
its interaction with Aurora B and Borealin for ﬁnal abscission to
occur and that the absence of Aurora B S227 phosphorylation
impairs exit from cytokinesis.
Together these data strongly indicate that PKCe and Aurora B
control abscission timing by regulating exit from the abscission
checkpoint. We propose a model in which PKCe acts directly
upstream of Aurora B thus maintaining CHMP4C away from the
midbody under conditions of chromatin retention in the furrow
(Fig. 4e).
Discussion
We have described an emergent role for PKCe in the ﬁnal
abscission checkpoint, where phosphorylation of the key mitotic
regulator Aurora B is required for successful exit and completion
of abscission. Aurora B and the CPC are involved in the
regulation of contractile ring formation through a number of
mechanisms, including modulation of RhoA activity and myosin
II binding to the cytoskeleton (for review see ref. 8) but has also
more recently been reported to play an active role in regulation of
abscission. First, retention of active Aurora B at the midbody
before abscission delays ﬁnal scission. This occurs in the presence
of chromatin trapped in the furrow, activating the NoCut or
abscission checkpoint1–5,15. In human cells, this delay in
abscission exit induces a stable intercellular canal at the
midbody, to allow for resolution of the chromatin bridge
between the two daughter cells3. Second, Aurora B is known to
phosphorylate key components of the abscission machinery
such as CHMP4C to delay abscission through preventing
the relocalization of the complexes to the abscission zone13
(Fig. 4d). Recently Petsalaki and Zachos15 demonstrated that the
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abscission checkpoint could be activated through Clk1, 2 or 4
phosphorylation of Aurora B at S331, resulting in CHMP4C S210
phosphorylation and delaying abscission until such time as the
chromatin trapped in the furrow was relieved. This suggests that
phosphorylation of Aurora B at S331 may provide the brake
for the abscission checkpoint, while S227 phosphorylation is the
release for exit and abscission.
We show that phosphorylation of S227 of Aurora B is not
required for the catalytic function of the kinase per se, rather it
plays a role in its action by altering substrate selection. The
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requirement for Aurora B to exist as one speciﬁc modiﬁed form
to enter cytokinesis and another to exit while retaining catalytic
activity is intriguing. It might be expected that the vast array of
Aurora B substrates will change with the morphological and
biochemical changes occurring in the cell during this time and
this is reﬂected in the need to switch speciﬁcity. While the
approach we adopted was to screen known substrates of Aurora B
based on the published literature and known consensus motifs,
screening different candidate sites and proteins for modiﬁcation
by both forms of Aurora B may prove insightful in determining
substrates selected by the T232-only phosphorylated species.
It has been proposed previously that Aurora B switches
preference to phosphorylate serine–proline motifs on
microtubule-associated substrates in cytokinesis rather than
threonine–proline motifs during mitosis11, although we have
not noted any such bias from our peptide screen. In Aurora A,
the corresponding serine can be phosphorylated by GSK3 to
reportedly negatively regulate the kinase in Xenopus larvae in
response to insulin and progesterone during oocyte maturation27;
we would speculate that this may also be a change of function
rather than inactivation.
The evidence indicates that when Aurora B S227 is not
phosphorylated, the cell fails abscission. This may be because the
cells fail to complete cytokinesis due to an inability to resolve the
trapped DNA and/or failure to exit the checkpoint. We have
demonstrated previously a critical role for PKCe in the response
to metaphase catenation20. The inhibition of PKCe activity
during the metaphase–anaphase transition leads to an increase in
the number of anaphase ultra-ﬁne bridges that persist through to
cytokinesis, activating the abscission checkpoint. The processive
changes the cell is undergoing at this time is consistent with the
hypothesis that S227 phosphorylation induces a switch in
substrate selection that would be required during these
transitions. We and others20,28 have demonstrated that some
tumour-derived cell models have a defective G2 catenation
checkpoint, meaning that they are more likely to enter mitosis
with residual catenation resulting in an increase in the number of
chromatin bridges as they traverse metaphase and anaphase.
We see evidence of this in the Aurora B S227A mutant cells
as the presence of PICH-positive structures in anaphase (Pike,
unpublished observations) increasing the likelihood of residual
DNA in the cytokinetic furrow, as well as the observed increase in
cells attempting to undergo cytokinesis after PKCe inhibition or
Aurora B S227A expression with Lap2b-positive chromatin
bridges we report here. We cannot rule out an additional
function for Aurora B S227 phosphorylation at the metaphase–
anaphase transition in these cells, especially when considering the
already reported role for PKCe and the integral role of Aurora B
during mitosis. Our results indicate however that independently
of this, PKCe has a speciﬁc role in cytokinesis where it triggers the
phosphorylation of Aurora B at S227.
The observed abscission failures with consequent binucleation
appears to be dependent on engagement of known components of
the abscission checkpoint indicating that it may be due to failure
to exit from the abscission checkpoint. This suggests that this
pathway is conditional on resolution of the non-disjunction
errors that cause chromatin to be trapped in the furrow,
phosphorylation occurring once all residual chromatin is
removed from the midzone, thereby ensuring that cytokinesis is
coordinated with completion of chromosome segregation. In the
cell models studied, PKCe appears to be required for Aurora B
phosphorylation in a high percentage of cytokinesis and failure of
this results in abscission failure. It therefore appears that the
abscission checkpoint is triggered in most cytokinesis. This may
be due to a necessity for this process in most cell divisions in
these speciﬁc cell lines reﬂecting the particular aneuploid state of
these models.
There now appears to be a complex set of functions of PKCe in
mitosis and cytokinesis. We propose a potentially pleiotropic role
for PKCe at the cytokinesis furrow, controlling the previously
deﬁned RhoA–Actin signalling pathway and, as deﬁned here,
modulating Aurora B function. Evidently, PKCe at the midbody
acts to control these processes in the context of the Aurora
B-dependent checkpoint, engaged in sensing the conditions
arising from non-disjunction and permitting completion of cell
division.
Methods
Reagents. All reagents were purchased from Sigma-Aldrich unless otherwise
stated. BLU577 was kindly provided by Dr Jon Roffey, Cancer Research
Technology, UK.
Cell culture. All cell lines were cultured in Dulbecco’s modiﬁed Eagle’s
medium (Gibco)þ 10% fetal calf serum and were obtained from the American
Type Culture Collection unless otherwise stated. For siRNA transfections,
Lullaby (OZ Biosciences) was used according to the manufacturer’s recommen-
dations; all siRNAs (Dharmacon) were used at a ﬁnal concentration of 20 nM.
Tetracycline-inducible DLD1 (a kind gift from Prof. Stephen Taylor) and 293 cell
lines (Invitrogen) were generated using the T-Rex Flp-In system (Invitrogen)
according to the manufacturer’s instructions. To induce GFP-Aurora B,
GFP-Borealin or GFP-PKCe expression, cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium containing 10% fetal calf serum and tetracycline (100 ngml 1) for
16 h before assay. Cells were treated for 30min with inhibitors unless otherwise
stated. Cell lines were routinely tested for mycoplasma.
Kinase assay. Assays were conducted in triplicate in 50 ml reactions containing
20mM Tris (pH 7.5), 5mM MgCl2, 0.5mM dithiothreitol (DTT), 0.2% Triton
X-100, 100 mM ATP and 5 mCi [g32P]-ATP (Amersham). Reactions were incubated
Figure 4 | PKCe and Aurora B inﬂuence CHMP4C localization during cytokinesis. (a) DLD1 GFP-Aurora B cell lines were transiently transfected with
three separate CHMP4C siRNA, imaged using live-cell time-lapse microscopy and scored for outcome of cytokinesis; successful cytokinesis resulting in
two daughter cells or failed cytokinesis resulting in a binucleate cell. Graph represents the mean (±s.e.m.) of three independent experiments; a minimum
of 50 cells were counted per experiment. Two-way analysis of variance (ANOVA), **¼ Pr0.01, ***¼ Pr0.001. (b) HeLa cells were transfected with PKCe
siRNA, a pool of three CHMP4C siRNA or PKCe siRNA and the pool of CHMP4C siRNA, imaged using live-cell time-lapse micrsocopy and scored for
outcome of cytokinesis as per the criteria above. Graph represents the mean (±s.e.m.) of three independent experiments; a minimum of 50 cells were
counted per experiment. Two way ANOVA, not signiﬁcant (NS)¼ P40.05, **¼ Pr0.01. (c) DLD1 GFP-Aurora B WT and S227A cell lines (green) were
transiently transfected with HA-CHMP4C (red) to look for midbody localization during cytokinesis. Cells were scored for the presence or absence of
HA-CHMP4C at the midbody. A minimum of 12 high-resolution, single-cell images per condition from four experiments were acquired; a representative
image is shown here. Scale bar, 10mm. Student’s t-test, *¼ Pr0.05. (d) DLD1 GFP-Borealin WTand S165A cell lines (green) were transiently transfected
with HA-CHMP4C (red) to look for midbody localization during cytokinesis. Cells were scored for the presence or absence of HA-CHMP4C at the
midbody. A minimum of ﬁve high-resolution, single-cell images per condition from two experiments were acquired; a representative image is shown here.
Scale bar, 10 mm. (e) Working model: chromatin trapped in the cytokinesis furrow engages the Aurora B-dependent abscission checkpoint. We propose that
the association through T232 only phosphorylated Aurora B and Borealin, CHMP4C is maintained in a S210 phosphorylated, closed, inactive conformer
distal to the midbody. On bridge resolution, PKCe phosphorylates Aurora B on S227, which in turn phosphorylates Borealin S165, allowing for CHMP4C to
assume an open, active conformation to polymerize with other ESCRT-III components and facilitate successful abscission.
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for 10min at 30 C using 100 ng of each kinase per reaction. Reactions were
terminated by spotting onto P81 cellulose paper or addition of 4 lysis buffer
(Invitrogen).
Cold kinase assays were conducted in 50 ml reactions containing 20mM Tris
(pH 7.5), 5mM MgCl2, 0.5mM DTT, 0.2% Triton X-100 and 100 mM ATP.
Reactions were incubated for 30min at 30 C using 1 mg of each recombinant
protein per reaction. Recombinant Borealin protein was purchased from Abcam
(ab107144). Reactions were terminated by addition of NuPAGE 4 LDS
sample buffer (Thermo Fisher) before western blotting with the appropriate
phospho-antibodies to detect kinase activity against speciﬁc phospho-sites.
Thermal shift assay. Thermal shift assays typically followed the protocol as
described in ref. 29. Brieﬂy, 100 ml of protein (B5 mg) in 50mM HEPES (pH7.6),
300mM NaCl, 5% glycerol and 1mM DTT was incubated with 20mM MgCl2
and 0–10 mM ATP for 30min at 4 C in the presence of 5 Sypro Orange dye
(Sigma-Aldrich). From the 100 ml reaction mixture per condition, 4 20 ml was
loaded onto RT–PCR plates in technical quadruplicates. Melting curves were then
assessed in an Applied Biosystems 7500 Fast RT–PCR system (Life Technologies).
Temperature was cycled up from 25 to 95 C in 1 Cmin 1 increments, with
measurements taken every 0.5 C.
Curves were trimmed manually and a Boltzmann Sigmoidal curve was ﬁtted to
the data in GraphPad Prism. The inﬂection point of the curve, Tm, was taken from
all conditions. The average Tm value of the untreated control replicates was
subtracted from the values of the treated wells to obtain the difference in Tm caused
by ATP binding, termed the DTm value.
Peptide array. Peptides predicted to be PKCe or Aurora B substrates were
identiﬁed and 15mers arrayed on nitrocellulose by the Peptide Synthesis laboratory
of the Francis Crick Institute. Membranes were blocked in 0.2mgml 1 BSA,
20mM Tris (pH7.5) and 0.02% Tween-20 overnight. Membranes were
subsequently incubated with the appropriate recombinant protein (PKCe kinase
domain 5 mg, Aurora B WT 100 mg and Aurora B S227A 100mg) and 10mMMgCl2
and 100 mM [g32P]-ATP (5 mCiml 1) for 10min followed by extensive washing in
H2O and acetic acid. Membranes were then exposed to ﬁlm before spot intensity
analysis using the ImageQuant TL7 (GE Lifesciences).
Proximity ligation assay. Cells were grown on eight-well-chambered slides
(Falcon) and ﬁxed as for immunoﬂuorescent imaging. Proximity ligation assay was
conducted using a kit (Sigma) as per the manufacturer’s instruction using the
antibody pairs anti-INCENP (rabbit) (Abcam ab12183), anti-Aurora B (mouse; BD
AIM1 no. 611082) and anti-Aurora B, anti-PKCe (rabbit; Abcam clone EPR1482
ab124806). Nonspeciﬁc IgG (rabbit sc-2027 and mouse sc-2025; Santa Cruz) were
used in conjunction with anti-Aurora B and anti-PKCe (respectively) as negative
controls to demonstrate the speciﬁcity of the proximity ligation assay reaction.
Constructs. Aurora B cDNA was a kind gift from Dr Mark Petronczski and was
cloned into pcDNA5/FRT/TO (Invitrogen) engineered to express an N-terminal
GFP using the InFusion cloning kit (BD) according to the manufacturer’s
instructions. For recombinant protein production, pET-Duet-1 Aurora B:INCENP
was a gift from Dr Jon Elkins, University of Oxford. RFP-Lap2B was purchased from
Addgene. Site-directed mutagenesis was completed using QuickChange mutagenesis
kit (Agilent) according to the manufacturer’s instructions. All clones were sequence
veriﬁed.
Microscopy. For live-cell time-lapse microscopy, cells were cultured on LabTek
chambered coverglass slides (Nunc) in Leibovitz CO2-independent media (Gibco).
A low light level inverted microscope (Nikon TE2000) imaging system equipped
with a laminar ﬂow heater to maintain a constant temperature of 37±0.01 C,
a PlanFluor  40 differential interference contrast (DIC) lens and a Xenon lamp
for ﬂuorescent excitation. Images were taken using a high-quantum efﬁciency
charge-coupled device camera (Andor Ixon) every 5min. Still images were taken
using an inverted laser scanning confocal microscope (Carl Zeiss LSM 780)
equipped with a  63 Plan-APOCHROMAT differential interference contrast
oil-immersion objective.
Immunoﬂuorescence and immunoblotting. For immunoﬂuorescence
experiments, cells were grown on 13mm glass coverslips and were simultaneously
ﬁxed and permeabilized in PTEMF buffer (4% paraformaldeyhyde, 0.2% Triton
X100, 20mM PIPES (pH 6.8), 10mM EGTA and 1mM MgCl2) for 30min.
The following primary antibodies were used in these assays are as follows: mouse
anti-Aurora B (AIM-1,611082, BD, 1:500); rabbit anti-Aurora B phosphoThr232
(TA325250, Origene, 1:300); rabbit anti-Aurora B phosphoSer227 (made in-house,
1:100); mouse anti-alpha tubulin (clone DM1A, T9026, Sigma, 1:1,000); rabbit
anti-INCENP (ab12183, Abcam, 1:300); mouse anti-Borealin (ab67126, Abcam,
1:300); mouse anti-Lap2B (611000, BD, 1:300); and mouse anti-HA.11 (clone
16B12, MMS-101P, Covance, 1:300). Primary antibodies were detected with Alexa
Fluor-conjugated secondary antibodies (Life Technologies). All coverslips were
mounted using ProLong Diamond with DAPI (Invitrogen).
For immunoblotting, cells were lysed in 1 NuPAGE LDS sample buffer
(Thermo Fisher Scientiﬁc) and sonicated for 3 10 s on ice. Proteins were
separated by SDS–PAGE and transferred to polyvinylidene diﬂuoride membranes
(Millipore). The following primary antibodies were used: mouse anti-Aurora B
(AIM-1,611082, BD, 1:2,000); rabbit anti-Aurora B phosphoThr232 (TA319253,
Origene, 1:1,000); rabbit anti-Aurora B phosphoSer227 (made in-house, 1:1,000);
mouse anti-alpha tubulin (clone DM1A, T9026, Sigma, 1:10,000); rabbit
anti-Borealin phosphoSer165 (made in-house, 1:500); mouse anti-Borealin
(ab67126, Abcam, 1:2,000); rabbit anti-Histone H3 (9715, Cell Signaling, 1:5,000);
rabbit anti-Histone H3 phosphoSer10 (9,701, Cell Signaling, 1:2,000); rabbit
anti-CHMP4C (GTX122876, Genetex, 1:1,000); and mouse anti-Histone H2AX
phosphoSer139 (clone JBW301 no. 05-636, Millipore, 1:5,000). Mouse and rabbit
horseradish peroxidase-conjugated secondary antibodies (NA931V and NA93V,
GE Lifesciences) were used at appropriate dilutions. Chemiluminescence was
detected using Luminata Classico western horseradish peroxidase substrate
(Millipore) and imaged using the ImageQuant 4000 mini (GE Lifesciences). Band
densitometry was carried out using Image J software and normalized to a loading
control. Whole membranes are presented in Supplementary Fig. 6.
Expression and puriﬁcation of Aurora B/INCENP. A pET-Duet vector encoding
human Aurora B (WT and S227A) and human INCENP WT (residues 837–918)
was transformed into electrocompetent Rosetta pLysS Escherichia coli cells. A 10ml
starter culture was used to inoculate 500ml of LB medium containing 100 mgml 1
ampicillin. The culture was grown at 37 C to an OD600 nm¼ 0.7. The cultures
were removed from the incubator and allowed to cool to room temperature.
Subsequently, isopropyl-b-D-thiogalactoside was added to a ﬁnal concentration
of 1mM and the cultures grown overnight at 20 C. The cells were pelleted by
centrifugation (2,000g for 10min) and re-suspended in 25ml of lysis buffer
(25mM Tris (pH 8.0), 1M NaCl, 1mM EDTA and 1mM DTT) with the
addition of a Roche Protease Inhibitor Cocktail Tablet. The cells were lysed by
a combination of lysozyme addition and 3 1000 sonication bursts. Subsequently,
polyethyleneimine (25 kDa, linear) was added to a ﬁnal concentration of
0.15% (w/v) and incubated on ice for 30min. Finally, the insoluble debris (and
polyethyleneimine–DNA complexes) was precipitated by centrifugation at 20K for
20min in an ultracentrifuge and ﬁltrated before puriﬁcation using an AKTA Pure
System (GE Healthcare) with a 1ml HisTrap column attached. The running buffer
was 25mM Tris (pH 8.0), 200mM NaCl, 1mM EDTA and 1mM DTT. The same
buffer supplemented with 500mM imidazole was used for elution. The proteins in
the peak were pooled and subjected to size exclusion using a Superdex200 10/300
column. Peaks containing both the Aurora B as well as the INCENP subunit were
pooled, concentrated and ﬂash-frozen in liquid N2 until use. Recombinant Aurora
B WT and S227A proteins were assessed for their phosphorylation state (pS227 and
pT232) and kinase activity against the substrate Histone H3 S10 before use in all
assays. At low efﬁciency of production of Aurora B, T232 but not S227 is phos-
phorylated. However, on highly efﬁcient production (that is, high concentration)
as determined using the above protocol, both sites become phosphorylated.
Expression and puriﬁcation of PKCe kinase domain. The cDNAs encoding
human PDK1 and a fusion protein consisting of glutathione S-transferase
(GST)-3C-PKCe (human, kinase domain) were inserted into the two multiple
cloning sites of the pFL vector (kind gift from Prof. Imre Berger, University of
Bristol). High-titre baculovirus stocks were generated using standard Bac-to-bac
(Invitrogen) protocols using Sf21 cells. For protein expression, 500ml of Sf21 cells
at 1 106 cells per ml grown in SF900-III medium (Life Technologies) were
infected with a multiplicity of infection of 1 for 72 h. The infection process was
monitored by cell counts and measurements of the insect cell diameter. The cells
were collected by centrifugation (2,000g for 10min) and re-suspended in 25ml of
GST-binding buffer (25mM HEPES, (pH 7.5), 125mM NaCl, 1mM DTT and
1mM EDTA) supplemented with a protease inhibitor tablet (Roche). The lysate
was loaded onto a 5ml GSTrap column (GE Healthcare) at 1mlmin 1, and
GST-3C-PKCe was eluted in binding buffer with 30mM reduced glutathione. The
fusion protein was cleaved overnight at 4 C with prescission protease. The cleavage
mixture was loaded onto a Resource15Q column at 1mlmin 1 and a linear NaCl
gradient (50–500mM) was applied. The PKCe kinase domain eluted as a single
peak around 300mM. The kinase-containing fractions were pooled and subjected
to a ﬁnal size-exclusion step using a Superdex 75 in a buffer containing 25mM
HEPES (pH 7.5), 125mM NaCl and 1mM TCEP.
Statistical analysis. For experiments where the data include more than two
conditions, a two-way analysis of variance using multiple comparisons was used, in
all other cases an unpaired t-test was used for analysis. Prism software (Graphpad)
was used for all calculations. The level of statistical signiﬁcance is represented as
follows: not signiﬁcant¼ P40.05, *¼ Pr0.05, **¼ Pr0.01, ***¼Pr0.001 and
****¼ Pr0.0001.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles, or are
available from the authors on request.
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